Showing Results for
- Academic Journals (24)
Search Results
- 24
Academic Journals
- 24
- Search Terms:
- 1From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedCurrent imaging techniques are unable to distinguish tumor recurrence from radiation necrosis, which represents a major challenge in neuro-oncology. Furthermore, radiation injury caused by newer antitumor therapies has...
- 2From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedChildren with relapsed acute lymphoblastic leukemia (ALL) have substantially better progression-free survival and overall survival when treated with induction therapy containing mitoxantrone compared with that...
- 3From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedThe importance of appropriate patient selection necessitates novel clinical trial design and biomarker-driven trials to allow delivery of the right drug to the right patient at the right time--personalized cancer...
- 4From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedThe outcomes in bladder cancer treated with radiotherapy are suboptimal. Recently, Hoskin et al. reported improved survival in patients with bladder cancer treated with radiation therapy with concurrent...
- 5From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedUnlike manual reading of cytology slides, which requires the cytoscreener to search the whole slide for abnormal cells, automated reading can selectively target abnormal cells on a slide. The MAVARIC trial compared the...
- 6From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedCurrent staging systems for patients with chronic lymphocytic leukemia (CLL)--the most common leukemia in the Western world--fail to precisely differentiate between indolent and aggressive forms. Molecular abnormalities...
- 7From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedThe systemic targeting of the VEGF pathway has, in recent years, been used to successfully treat a number of solid cancers. Drugs that target this pathway--which include the antibody bevacizumab--disrupt angiogenesis in...
- 8From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedA long-term follow-up study that assessed the effect of daily aspirin on colorectal cancer incidence concluded that it significantly reduced the risk of colon cancer, but not rectal cancer. Detailed analysis of the...
- 9From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedYounes, A. Nat. Rev. Clin. Oncol. 8, 85-96 (2010); doi:10.1038/nrclinonc.2010.189 In the February 2011 issue of Nature Reviews Clinical Oncology, two errors were published in the Review article by Anas Younes. On...
- 10From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedThree advances are dramatically changing the landscape of oncology. First, hundreds of drugs are available that inhibit targets involved in oncogenesis. Second, efforts to reclassify malignant diseases are expanding the...
- 11From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedImatinib was discontinued in patients with chronic myeloid leukemia (CML) who gained a complete molecular response (cMR). Of those patients with at least 12 months follow-up, 61% experienced recurrence, all of whom...
- 12From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedTumor biomarker studies may generate insights into the biological characteristics that drive the clinical behavior of a cancer. Publication bias and hidden multiple hypotheses testing distort the assessment of the true...
- 13From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedAround 30-40% of patients receiving anticancer drugs experience chemotherapy-induced peripheral neuropathy. Direct nerve stimulation has been suggested as a technique to reduce this pain. Smith and colleagues tested a...
- 14From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedFor patients with colon cancer, treatment with oxaliplatin is an option with curative potential for those with early-stage disease, and in patients presenting later it is used to prolong survival. Unfortunately, this...
- 15From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedTransvaginal ultrasound has been suggested as a possible screening method for endometrial cancer, owing to its value in assessing symptomatic patients with a predisposition to the disease. In the first large-scale study...
- 16From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedTreatment with the ABL kinase inhibitor imatinib is extremely effective and has induced complete responses in more than 80% of patients with chronic myeloid leukemia (CML). However, most patients experience disease...
- 17From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedColoprint[R] is an 18-gene expression signature designed to predict disease relapse in patients with early-stage colorectal cancer (CRC). We discuss the potential impact of Coloprint[R] on clinical practice, and its...
- 18From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedThere is an urgent need for blood-based, noninvasive molecular tests to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions are still possible....
- 19From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedNowhere has the evolution of personalized medicine been more rapid than the field of oncology. Advances in drug development, identification of multiple disease subtypes, and available high-throughput technologies have...
- 20From: Nature Reviews Clinical Oncology. (Vol. 8, Issue 3) Peer-ReviewedElucidation of the genetic processes leading to neoplastic transformation has identified cancer-promoting molecular alterations that can be selectively targeted by rationally designed therapeutic agents. Protein kinases...